Skip to main content
. Author manuscript; available in PMC: 2015 Oct 2.
Published in final edited form as: Future Oncol. 2012 Aug;8(8):961–987. doi: 10.2217/fon.12.95

Figure 2. Combination of HER-2 vaccines and VEGF peptide mimics.

Figure 2

HER-2 vaccines and VEGF peptide inhibitors developed in our laboratories to inhibit signaling pathways. Antibodies elicited by immunization with MVF-HER-2 (266–296) vaccine bind to domain II of HER-2 and, similarly, anti-MVF-HER-2 (597–626) binds domain IV of HER-2, providing dual inhibition of homo/heterodimerization, and consequently downstream signaling, shutting down the PI3K and MAPK pathways, thereby preventing cancer growth and metastasis. On the other hand, VEGF peptide mimics P3 and P4, which are designed to directly block VEGF binding to VEGFR-2, inhibit intracellular phosphorylation of the tyrosine kinase domain, which reduces angiogenesis.

EGFR: EGF receptor; P: Phosphate; VEGFR: VEGF receptor.